Rebecca Robertson Sells 2,500 Shares of CeriBell (NASDAQ:CBLL) Stock

January 7, 2026 by InsiderTrades.com

Key Points

CTO Raymond Woo sold 11,112 shares at an average price of $21.18 on Jan. 2 for $235,352.16, reducing his stake by about 6.23% after similar sales in November and December.
FDA Breakthrough Device designation was awarded for CeriBell’s LVO stroke detection/monitoring system, which could speed regulatory review and support wider hospital and payor adoption.
Shares opened higher (up ~4.4%) with a market cap near $806 million; the company beat recent quarterly revenue and EPS estimates but remains unprofitable, and analysts hold a consensus "Moderate Buy" with a $24.67 target.

CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) Director Rebecca Robertson sold 2,500 shares of the company's stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $21.89, for a total transaction of $54,725.00. Following the sale, the director owned 19,576 shares of the company's stock, valued at $428,518.64. This trade represents a 11.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

CeriBell Trading Up 4.4%

CeriBell stock opened at $21.73 on Wednesday. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $26.04. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. The firm has a market capitalization of $806.18 million, a PE ratio of -14.39 and a beta of 1.02. The business's 50-day simple moving average is $17.33 and its 200-day simple moving average is $14.97.

CeriBell (NASDAQ:CBLL - Get Free Report) last announced its earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. The firm had revenue of $22.59 million during the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. Equities research analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Institutional Investors Weigh In On CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of CBLL. Ameritas Investment Partners Inc. raised its stake in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock valued at $48,000 after buying an additional 1,256 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in CeriBell by 353.8% in the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after acquiring an additional 1,801 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell in the third quarter valued at about $33,000. Rhumbline Advisers lifted its stake in CeriBell by 26.5% during the first quarter. Rhumbline Advisers now owns 15,629 shares of the company's stock worth $300,000 after purchasing an additional 3,276 shares during the period. Finally, Sei Investments Co. boosted its holdings in CeriBell by 7.1% during the third quarter. Sei Investments Co. now owns 50,454 shares of the company's stock valued at $580,000 after purchasing an additional 3,365 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CBLL. BTIG Research reaffirmed a "buy" rating and set a $30.00 target price on shares of CeriBell in a research report on Monday, December 15th. JPMorgan Chase & Co. dropped their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating on the stock in a report on Wednesday, November 5th. Canaccord Genuity Group upped their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a "buy" rating in a research report on Wednesday, December 17th. TD Cowen decreased their target price on CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. Finally, Cowen restated a "buy" rating on shares of CeriBell in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, CeriBell presently has a consensus rating of "Moderate Buy" and an average price target of $24.67.

View Our Latest Stock Report on CeriBell

CeriBell News Summary

Here are the key news stories impacting CeriBell this week:

Positive Sentiment: FDA Breakthrough Device designation for CeriBell’s LVO stroke detection/monitoring system — the designation raises the product’s regulatory profile and can accelerate review and access, supporting revenue growth and credibility with hospitals and payors. Ceribell Receives FDA Breakthrough Device Designation
Neutral Sentiment: Multiple media/analyst outlets are reporting the designation, amplifying investor awareness and likely driving short-term trading interest without adding new technical detail. Zacks: CBLL Wins FDA Breakthrough Status
Neutral Sentiment: Recent fundamentals: the company beat the last quarter’s revenue and EPS estimates but remains unprofitable with negative margins and analyst forecasts for negative full-year EPS — supportive for growth narrative but underscores ongoing execution and profitability risk.
Negative Sentiment: Insider sale — CTO Raymond Woo sold 11,112 shares at an average $21.18 on Jan. 2, reducing his stake by ~6.2%; disclosed via SEC filing. Insider selling can be interpreted by some investors as a signal to trim exposure. SEC Filing: Raymond Woo
Negative Sentiment: Insider sale — Director Rebecca B. Robertson sold 2,500 shares at an average $21.89 on Jan. 2, a roughly 11.3% reduction in her position; disclosed via SEC filing. SEC Filing: Rebecca B. Robertson

CeriBell Company Profile

(Get Free Report)

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.